The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Filimonkova N.N.

Ural Research Institute of Dermatovenerology and Immunopathology, Ekaterinburg

Vorob'eva Iu.V.

FGBU Ural'skiĭ nauchno-issledovatel'skiĭ institut dermatovenerologii i immunopatologii MZ RF, Ekaterinburg

Topychkanova E.P.

FGBU "Ural'skiĭ nauchno-issledovatel'skiĭ institut dermatovenerologii i immunopatologii" Minzdrava Rossii

Hepatoprotectors and zinc pyrithione in the combination therapy of patients with psoriasis

Authors:

Filimonkova N.N., Vorob'eva Iu.V., Topychkanova E.P.

More about the authors

Read: 7517 times


To cite this article:

Filimonkova NN, Vorob'eva IuV, Topychkanova EP. Hepatoprotectors and zinc pyrithione in the combination therapy of patients with psoriasis. Russian Journal of Clinical Dermatology and Venereology. 2013;11(5):79‑83. (In Russ.)

References:

  1. Kungurov N.V., Filimonkova N.N., Tuzankina I.A. Psoriaticheskaya bolezn'. Ekaterinburg: Izd. Ural'skogo universiteta 2002.
  2. Kubanova A.A., Kubanov A.A., Nikolas Dzh. F. i dr. Immunnye mekhanizmy psoriaza. Novye strategii biologicheskoi terapii. Vestn dermatol i venerol 2010; 1: 35-47.
  3. Krueger J.G., Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64: 30-36.
  4. Mordovtsev V.N., Mushet G.V., Al'banova V.I. Psoriaz. Patogenez, klinika, lechenie. Kishinev: Shtiintsa 1991.
  5. Christophers E. Psoriasis - epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 4: 314-320.
  6. Barker J.W.N. Pathogenesis and clinic features of psoriasis. Lancet 2007; 370: 263-271.
  7. Nickoloff B.J. The immunologic and Genetic Basis of Psoriasis. Arch Dermatol 1999; 135: 1104-1110.
  8. Holm S.J., Sanchez F., Carlen L.M. Genetics of psoriasis. Acta Derm Venereol 2005; 85: 1: 2-8.
  9. Dovzhanskii S.I., Utts S.R. Psoriaz ili psoriaticheskaya bolezn'. Saratov 1992.
  10. Filimonkova N.N. Psoriaticheskaya bolezn': kliniko-immunologicheskie varianty, patogeneticheskoe obosnovanie differentsirovannoi terapii: Avtoref. dis. … d-ra med. nauk. Chelyabinsk 2001.
  11. Miyaji C., Miyakawa R., Watanabe H., Kawamura H., Abo T. Mechanisms underlying the activation of cytotoxic function mediated by hepatic lymphocytes following the administration of glicyrrhizin. Int Immunopharmacol 2002; 2: 8: 1079-1086.
  12. Katunina O.R. Immunnaya sistema kozhi i ee rol' v lechenii psoriaza. Vestn dermatol i venerol 2005; 1: 19-23.
  13. Korsun V.F., Korsun A.F. Psoriaz. SpB: Dilya 1999.
  14. Storozhakov G.I., Baikova I.E. Glitsirrizin v lechenii khronicheskikh virusnykh gepatitov. Klin farmakol i ter 2000; 9: 39-41.
  15. Zlatkov N.B. Psoriazis. Sofiya 1984.
  16. Menter A., Griffiths C.E. Current and future management of psoriasis. Lancet 2007; 370: 272-284.
  17. Krueger J.G., Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005; 64: 30-36.
  18. Kubanova A.A. Klinicheskie rekomendatsii. Dermatovenerologiya. M 2007.
  19. Nickoloff B.J., Nestle F.O. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004; 15: 1664-1675.
  20. Ipatova O.M. Fosfogliv: mekhanizm deistviya i primenenie v klinike. Pod red. akad. RAMN A.I. Archakova. M: Izd-vo GU NII biomeditsinskoi khimii RAMN 2005.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.